-

03:30:14 PM

TNXP Stock News

TNXP - Tonix Pharmaceuticals Holding Corp

05/26/21 7:00 AM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced that it will present two posters at the 2021 American

RHEA-AI

neutral

05/12/21 7:00 AM

Nasdaq : TNXP

conferences

Tonix Pharmaceuticals to Present at May Investor Summit Virtual Conference

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company

RHEA-AI

neutral

05/10/21 4:30 PM

Nasdaq : TNXP

earnings

Tonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights

Announced Positive Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800 Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia Expected in Third Quarter 2021 Deep Pipeline Progressing with Three Central Nervous System (CNS) Programs Expected to Enter Phase 2

RHEA-AI

neutral

04/21/21 7:00 AM

Nasdaq : TNXP

conferences

Tonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation Forum

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, was invited to deliver a company

RHEA-AI

neutral

04/19/21 7:00 AM

Nasdaq : TNXP

covid-19

Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, and OyaGen,

RHEA-AI

very positive

04/07/21 7:00 AM

Nasdaq : TNXP

conferences

Tonix Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company

RHEA-AI

neutral

03/22/21 2:30 PM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today

RHEA-AI

neutral

03/19/21 7:00 AM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,946,027 to the Company on March 16, 2021.

RHEA-AI

neutral

03/17/21 7:00 AM

Nasdaq : TNXP

covid-19

Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2

Vaccine Candidate TNX-1800 Protected Both Upper and Lower Airways After Challenge with SARS-CoV-2, Suggesting an Ability to Block Forward Transmission TNX-1800 is Based on a Proprietary Vaccine Platform Designed to Stimulate Long Term T cell Immunity CHATHAM, N.J., March 17, 2021

RHEA-AI

neutral

03/15/21 4:45 PM

Nasdaq : TNXP

earnings

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Interim Analysis Results from Second Confirmatory Phase 3 Study, RALLY, Expected in Third Quarter 2021: Interim Cohort Enrolled Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 8 Next

TNXP Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.tonixpharma.com
CeoSeth Lederman
Security nameTonix Pharmaceuticals Holding Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees26
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address26 Main Street, Suite 101
StateNew Jersey
CityChatham
Zip07928
CountryUnited States
Phone12129809155

TNXP Description:

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the third quarter of 20212 and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-18003, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.